Use of certain phenyl-naphthyl compounds that do not have significant affintiy to ER alpha or beta for protection of neurons and oligodendrocytes in the treatment of multiple sclerosis

Details for Australian Patent Application No. 2005323241 (hide)

Owner Aventis Pharmaceuticals Inc.

Inventors Funes, Sandrines; Merrill, Jean E.; Chandross, Karen; Wirtz-Brugger, Friederike; Petko, Wayne

Agent Watermark

Pub. Number AU-A-2005323241

PCT Pub. Number WO2006/073714

Priority 60/640,930 31.12.04 US

Filing date 14 December 2005

Wipo publication date 13 July 2006

International Classifications

A61K 31/05 (2006.01)

A61K 31/055 (2006.01)

A61P 25/28 (2006.01) Drugs for disorders of the nervous system

Event Publications

26 July 2007 PCT application entered the National Phase

  PCT publication WO2006/073714 Priority application(s): WO2006/073714

17 December 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005323242-Use of selected compounds for protection of neurones and oligodendrocytes in the treatment of multiple sclerosis

2005323240-Feed nozzle assembly and burner apparatus for gas/liquid reactions